Navigation Links
Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008

IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced that the company will celebrate a number of cardiac surgery milestones and product debuts at the 88th annual meeting of the American Association for Thoracic Surgery (AATS), May 10-14 in San Diego.

Among the milestones marked by Edwards -- which this year celebrates its 50th anniversary of partnering with clinicians to develop life-saving innovations -- are:

-- The treatment of more than 1 million patients worldwide with Edwards'

heart valve repair and replacement technologies.

-- The implantation of the Edwards SAPIEN transcatheter aortic heart valve

in more than 1,000 patients worldwide through a series of extensive

clinical trials and feasibility studies in Europe, the U.S. and Canada,

as well as commercial sales in Europe.

-- The start of patient enrollment for transcatheter aortic valve

replacement procedures with the Ascendra transapical delivery system at

participating sites in Edwards' U.S. pivotal trial of the Edwards

SAPIEN valve. Edwards has conditional approval from the U.S. Food and

Drug Administration to perform procedures with both the Ascendra

transapical delivery system and the RetroFlex transfemoral delivery

system at the PARTNER trial sites.

-- Regulatory and reimbursement approval received this week from the

Japanese Ministry of Health for the Carpentier-Edwards PERIMOUNT Magna

pericardial aortic heart valve. As the first and only device of its

kind, this valve combines more than 20 years of clinical experience and

innovation with the most advanced tissue engineering technologies. The

PERIMOUNT Magna valve is the best selling tissue valve in the world.

New Products

Edwards is also introducing and unveiling several new products at AATS:

-- Edwards is offering new arterial and venous cannulae, which are the

flexible tubes used to establish cardiopulmonary bypass in cardiac

surgery. The new cannulae are designed to reduce trauma, increase

efficiency and provide a variety of cannulation site options that

address today's more challenging surgical approach. Among these are the

FemTrak femoral venous cannula and the OptiSite arterial cannula, which

both have proprietary ultra-thin wall technology to help optimize blood

flow while a patient is on a heart-lung machine.

-- The next-generation of the Carpentier-Edwards Physio annuloplasty ring

will be unveiled. This product addresses the degenerative segment of

mitral valve repair -- the largest segment within the repair market --

and features a ring design that better conforms to the patient's

natural anatomy. The original Carpentier-Edwards Physio ring is the

number-one global repair product and was launched in 1994.

"This year Edwards celebrates 50 years of working closely with the surgical community on the development of our pioneering heart valve repair and replacement products and cardiac surgery tools. We look forward to extending this partnership with surgeons as our industry continues to evolve," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "We will continue this valuable collaboration with surgeons to help shape the emerging minimally-invasive surgery practice and develop transformational therapies for patients. The new Edwards products featured at AATS will also support this goal."

Representatives from Edwards will be in the exhibition area at booth #1001. The booth features information on the new products and simulators for hands-on experience in transcatheter and minimally-invasive surgery techniques.

Clinical Presentations

Among the clinical presentations featuring data about Edwards' devices are:
Sunday, May 11

-- Session V, Percutaneous Aortic Valve Replacement: Update on

Percutaneous AVR with Edwards SAPIEN Valve (retrograde and antegrade)

-- 4:15 p.m. to 4:35 p.m. Ballroom 20 A-C, San Diego Convention

Center. Presenter: John G. Webb, St. Paul's Hospital, Vancouver, BC,


-- Session V, Percutaneous Aortic Valve Replacement: Identification of

Appropriate Patients: Who Actually is "Inoperable"? -- 4:55 p.m. to

5:15 p.m. Ballroom 20 A-C, San Diego Convention Center. Presenter:

Michael J. Mack, Cardiothoracic Surgery Associates of North Texas,

Dallas, TX.

Wednesday, May 14

-- Emerging Technologies and Techniques Forum: Is Transcatheter Based

Aortic Valve Implantation Really Less Invasive than Minimal Invasive

Aortic Valve Replacement? -- 7:13 a.m. to 7:26 a.m. Room 25, San Diego

Convention Center. Presenters/authors: Mirko Doss, Sven Martens,

Stephan Fichtelscherer, Thomas Trepels, Gerhard Wimmer Greinecker,

Anton Moritz, Volker Schachinger, Thoracic and Cardiovascular Surgery,

J.W. Goethe University Frankfurt, Frankfurt am Main, Germany.

-- Emerging Technologies and Techniques Forum: Transapical Transcatheter

Aortic Valve Implantation One Year Follow-Up in 19 Patients --

8:05 a.m. to 8:18 a.m. Room 25, San Diego Convention Center.

Presenters/authors: Jian Ye, Anson Cheung, John G. Webb, Daniel R.

Wong, Ronald G. Carere, Christopher R. Thompson, Samuel V.

Lichtenstein, Cardiothoracic Surgery, University of British Columbia,

Vancouver, BC, Canada.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

Edwards, Edwards SAPIEN, FemTrak, OptiSite and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Ascendra, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna, Carpentier-Edwards Physio and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
2. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
3. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
6. Edwards Lifesciences Forecasts Strong Growth in 2008
7. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
8. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
9. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
10. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Edwards Lifesciences Announces Organizational Changes
Post Your Comments:
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
(Date:10/13/2015)... New York , October 13, 2015 ... Growth, Trends, and Forecast 2015 - 2023 " , ... in 2014 and is anticipated to reach US$7.59 bn by 2023, ... 2015 to 2023. --> " Microbiology Culture Market ... - 2023 " , the global microbiology culture ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx Inc. , a ... received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). This Phase ... Sciences (NIGMS), will fund the development of a technique to rapidly convert single-chain ...
(Date:10/13/2015)... YORK , October 13, 2015 ... acceleration and development company, has entered into a strategic ... York and Paris, France ... --> --> This collaborative arrangement ... highly respected scientific advisory team as well as long ...
Breaking Biology Technology:
(Date:10/12/2015)... October 12, 2015 NXTD ) ("NXT-ID" ... growing mobile commerce market, reports on the recent SNS Future ... . --> NXTD ) ("NXT-ID" or the "Company"), ... market, reports on the recent SNS Future in Review Conference ... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ...
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
(Date:10/6/2015)... SALT LAKE CITY , Oct. 6, 2015 /PRNewswire/ ... solutions company, announced today that it has signed a ... electronic monitoring services across the full range of sentences ... Track Group,s President of the Americas. "This contract with ... Eastern region of the US and advances our position ...
Breaking Biology News(10 mins):